Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 23, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 900,000 ordinary shares of 25 pence each.
- Purchase Price: 1,337.0921 pence per share.
- Treasury Shares Held: 225,089,678 shares (post-transaction).
- Shares in Issue: 5,764,423,512 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed the purchase on November 23, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 900,000 share repurchase against the stated price of 1,337.0921 pence.
- Confirm the updated total share count (5,764,423,512 in issue) against subsequent filings.
- Review the remaining authorization limit for share buybacks under the May 17, 2006 shareholder resolution.